Literature DB >> 17632267

Redefining the clinical spectrum of chronic pulmonary histoplasmosis: a retrospective case series of 46 patients.

Cassie C Kennedy1, Andrew H Limper.   

Abstract

Chronic pulmonary histoplasmosis is a disorder caused by Histoplasma capsulatum infection that is classically described as cavitary disease in male smokers with underlying chronic obstructive pulmonary disease (COPD). This clinical description relies on previous studies conducted mainly on cohorts from tuberculosis sanatoriums and United States Department of Veterans Affairs hospitals. Patients in earlier series were often selected either after being suspected of having Mycobacteria tuberculosis or by the presence of cavitary disease on chest radiograph. These early studies therefore may overrepresent the true proportion of males, smokers, and the percentage with cavitary disease in the general population. We sought to define the clinical spectrum of chronic pulmonary histoplasmosis in a mixed-sex inpatient and outpatient population. We conducted a retrospective chart review from 1976 to 2000 on all adults with a diagnosis of histoplasmosis with symptoms suggestive of pulmonary histoplasmosis for > or =6 weeks and either significantly positive serum H. capsulatum antibody titers or positive cultures (without evidence of disseminated disease). Participants included 46 patients, with a median age of 56 years. Notable differences were found between our study population and those in previously reported studies. First, nearly half of our patients were women (48%), and one-quarter were life-long nonsmokers (27%). Only 39% had cavitary disease and only 20% had COPD. It is noteworthy that there were no positive cultures from those patients who had never smoked. Major differences existed between male and female participants. Female patients had a lower presence of cavities, a decreased number of smokers and extent of smoking exposure, a decreased number of positive cultures, and an absence of underlying COPD. To our knowledge, this study is the first to report on a large number of outpatients with chronic pulmonary histoplasmosis. In contrast to previous studies, the current study included 48% female patients, 27% never smokers, and only 39% of patients with cavitary disease, representing a noticeably different spectrum of disease compared to previous studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632267     DOI: 10.1097/MD.0b013e318144b1d9

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  11 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  Imported African histoplasmosis in an immunocompetent patient 40 years after staying in a disease-endemic area.

Authors:  Clémence Richaud; Marie-Olivia Chandesris; Fanny Lanternier; Hélène Benzaquen-Forner; Dea Garcia-Hermoso; Capucine Picard; Emilie Catherinot; Marie-Elisabeth Bougnoux; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2014-09-22       Impact factor: 2.345

3.  Pulmonary Histoplasmosis in a Referral Hospital in Mexico City.

Authors:  Alejandro Hernández Solís; Javier Araiza Santibáñez; Jazmín Guadalupe Tejeda Olán; Andrea Quintana Martínez; Alejandro Hernández de la Torriente; Rocio de la Torriente Mata
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-06-24       Impact factor: 2.585

4.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

5.  Histoplasma-associated inflammatory pseudotumour of the kidney mimicking renal carcinoma.

Authors:  Michael A den Bakker; Natascha N T Goemaere; Juliëtte A Severin; J L Nouwen; Paul C M S Verhagen
Journal:  Virchows Arch       Date:  2009-01-06       Impact factor: 4.064

6.  A Case of Refractory Pulmonary Coccidioidomycosis Successfully Treated with Posaconazole Therapy.

Authors:  R H Patel; S Pandya; S Nanjappa; J N Greene
Journal:  J Fam Med       Date:  2017-11-21

7.  Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection.

Authors:  Benjamin J Murdock; Seagal Teitz-Tennenbaum; Gwo-Hsiao Chen; Anthony J Dils; Antoni N Malachowski; Jeffrey L Curtis; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2014-09-15       Impact factor: 5.422

8.  A Red Flag for Community-Acquired Pneumonia in the Elderly.

Authors:  Tanmay S Panchabhai; Debabrata Bandyopadhyay; Valeria Arrossi; Kyle D Brizendine; Muzaffar Ahmad
Journal:  J Glob Infect Dis       Date:  2015 Jul-Sep

9.  Mapping histoplasmosis in South East Asia - implications for diagnosis in AIDS.

Authors:  Jacob Baker; Findra Setianingrum; Retno Wahyuningsih; David W Denning
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

Review 10.  Chronic Pulmonary Histoplasmosis-A Scoping Literature Review.

Authors:  Jacob Baker; Chris Kosmidis; Anna Rozaliyani; Retno Wahyuningsih; David W Denning
Journal:  Open Forum Infect Dis       Date:  2020-04-06       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.